The stock price of Verona Pharma Plc ADR (NASDAQ: VRNA) has surged by 3.73 when compared to previous closing price of 45.04, but the company has seen a 16.63% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-19 that LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in December 2024:
Is It Worth Investing in Verona Pharma Plc ADR (NASDAQ: VRNA) Right Now?
Company’s 36-month beta value is 0.42.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for VRNA is 68.91M, and currently, short sellers hold a 9.61% ratio of that floaft. The average trading volume of VRNA on December 27, 2024 was 1.00M shares.
VRNA’s Market Performance
VRNA’s stock has seen a 16.63% increase for the week, with a 17.74% rise in the past month and a 69.03% gain in the past quarter. The volatility ratio for the week is 5.51%, and the volatility levels for the past 30 days are at 4.21% for Verona Pharma Plc ADR The simple moving average for the last 20 days is 13.59% for VRNA stock, with a simple moving average of 88.81% for the last 200 days.
Analysts’ Opinion of VRNA
Many brokerage firms have already submitted their reports for VRNA stocks, with Wells Fargo repeating the rating for VRNA by listing it as a “Overweight.” The predicted price for VRNA in the upcoming period, according to Wells Fargo is $50 based on the research report published on October 03, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see VRNA reach a price target of $38, previously predicting the price at $35. The rating they have provided for VRNA stocks is “Buy” according to the report published on May 22nd, 2023.
Wedbush gave a rating of “Outperform” to VRNA, setting the target price at $27 in the report published on September 19th of the previous year.
VRNA Trading at 22.00% from the 50-Day Moving Average
After a stumble in the market that brought VRNA to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 1.61% of gains for the given period.
Volatility was left at 4.21%, however, over the last 30 days, the volatility rate increased by 5.51%, as shares surge +17.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +37.13% upper at present.
During the last 5 trading sessions, VRNA rose by +16.63%, which changed the moving average for the period of 200-days by +183.50% in comparison to the 20-day moving average, which settled at $41.13. In addition, Verona Pharma Plc ADR saw 135.01% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRNA starting from ZACCARDELLI DAVID, who sale 640,264 shares at the price of $5.01 back on Dec 05 ’24. After this action, ZACCARDELLI DAVID now owns 14,367,552 shares of Verona Pharma Plc ADR, valued at $3,205,226 using the latest closing price.
ZACCARDELLI DAVID, the President and CEO of Verona Pharma Plc ADR, sale 162,800 shares at $5.01 during a trade that took place back on Dec 06 ’24, which means that ZACCARDELLI DAVID is holding 14,204,752 shares at $815,400 based on the most recent closing price.
Stock Fundamentals for VRNA
Current profitability levels for the company are sitting at:
- -23.71 for the present operating margin
- 0.8 for the gross margin
The net margin for Verona Pharma Plc ADR stands at -23.45. The total capital return value is set at -0.44. Equity return is now at value -78.35, with -45.78 for asset returns.
Based on Verona Pharma Plc ADR (VRNA), the company’s capital structure generated 0.48 points at debt to capital in total, while cash flow to debt ratio is standing at -0.86. The debt to equity ratio resting at 0.93. The interest coverage ratio of the stock is -11.23.
Currently, EBITDA for the company is -52.47 million with net debt to EBITDA at 1.71. When we switch over and look at the enterprise to sales, we see a ratio of 549.88. The receivables turnover for the company is 0.39for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.03.
Conclusion
In a nutshell, Verona Pharma Plc ADR (VRNA) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
